BioSyntech, Inc: Canadian IPO.Business Editors/High-Tech Writers LAVAL, Quebec--(BUSINESS WIRE)--March 22, 2004 BioSyntech, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :BSYI) is pleased to announce that its final prospectus Final Prospectus A legal document stating the price of a newly issued security, the delivery date, and other facts that are important for investors. Notes: The final prospectus must be given to every investor who purchases a new issue of registered securities. has been filed with the regulatory authorities in the provinces of Quebec, Ontario, Manitoba, Alberta and British Columbia British Columbia, province (2001 pop. 3,907,738), 366,255 sq mi (948,600 sq km), including 6,976 sq mi (18,068 sq km) of water surface, W Canada. Geography , for the sale of up to 4,000,0000 units at a price of CAN $1.25 per Unit. Each unit includes one common share and half of one warrant. A first closing has been scheduled for March 29, 2003. Canaccord Capital Corporation is acting as agent for BioSyntech in the context of the offering. The securities offered have not and will not be registered under the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. Securities Act of 1933, as amended and subject to certain exemptions from registration, may not be offered or sold, or otherwise transferred, directly or indirectly, in the United States of America UNITED STATES OF AMERICA. The name of this country. The United States, now thirty-one in number, are Alabama, Arkansas, Connecticut, Delaware, Florida, Georgia, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Mississippi, Missouri, New Hampshire, , its territories or possessions, or to U.S. Persons. About BioSyntech - BioSyntech is a biotechnology company specializing in the discovery, development and manufacturing of regenerative medicine products and therapeutic delivery systems. THIS PRESS RELEASE CONTAINS CERTAIN "FORWARD-LOOKING" STATEMENTS, AS DEFINED IN THE UNITED STATES PRIVATE SECURITIES LITIGATION REFORM ACT The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and OF 1995 THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES. THERE CAN BE NO ASSURANCE THAT SUCH STATEMENTS WILL PROVE TO BE ACCURATE AND THE ACTUAL RESULTS AND FUTURE EVENTS COULD DIFFER MATERIALLY FROM MANAGEMENTS CURRENT EXPECTATIONS, SUCH FACTORS ARE DETAILED FROM TIME TO TIME IN THE COMPANY'S FILINGS WITH THE REGULATORY AUTHORITIES HAVING JURISDICTION. NO REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED THE CONTENT OF THIS RELEASE. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion